- Home
- INMD vs GERN Comparison
INMD vs GERN Comparison
Compare INMD & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMD | GERN |
|---|---|---|
| Founded | 2008 | 1990 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 879.2M | 900.1M |
| IPO Year | 2019 | 1996 |
Fundamental Metrics
Financial Performance| Metric | INMD | GERN |
|---|---|---|
| Price | $14.48 | $1.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $16.75 | $3.00 |
| AVG Volume (30 Days) | 1.4M | ★ 13.9M |
| Earning Date | 02-10-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $370,495,000.00 | $183,403,000.00 |
| Revenue This Year | $5.40 | $146.80 |
| Revenue Next Year | $4.80 | $30.21 |
| P/E Ratio | $10.00 | ★ N/A |
| Revenue Growth | N/A | ★ 522.13 |
| 52 Week Low | $13.14 | $1.04 |
| 52 Week High | $19.78 | $2.84 |
Technical Indicators
Market Signals| Indicator | INMD | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 46.62 | 76.49 |
| Support Level | $14.23 | $1.55 |
| Resistance Level | $14.55 | $1.69 |
| Average True Range (ATR) | 0.54 | 0.11 |
| MACD | -0.13 | 0.03 |
| Stochastic Oscillator | 12.30 | 92.24 |
Price Performance
Historical ComparisonAbout INMD InMode Ltd.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.